Abiraterone, an experimental cancer drug under trial, has potential for shrinking prostate tumors at a fast rate and giving cancer patients double the chance of survival in 70 to 80 percent of patients with aggressive cancers.

The study has a small trial sample of 21 patients, although the medication was first tested in over 250 men with similar positive results

A new drug could potentially save the lives of thousands of prostate cancer sufferers, new studies have shown, while eliminating the need for damaging chemotherapy and radiotherapy.

The drug, abiraterone, works by blocking the hormones which fuel the cancer and a human trial has shown that it can shrink tumors in up to 80 percent of cases. The technique could also be effective on other tumors, such as breast and bowel cancers, Britain's Daily Mail reported

Most Canadian citizens are likely to survive the often fatal disease of cancer because of the country's accessible and reliable health care system, according to a Concord study.

The study, which will appear in the August issue of The Lancet Oncology, revealed that Canada ranked second in patient survival for breast cancer, third for prostate cancer in men and for colorectal cancer in women, and sixth for colorectal cancer in men

An international study, the Concord Report, comparing cancer survival rates in 31 nations for four types of cancer, shows that the U.S. topped survival rates for breast and prostate cancer, while for colorectal cancer, Japan led the men's category and France the women's category.

Canada ranked high in the four categories, indicating the good access rate of Canadian cancer patients to quality health care

Biotech drug manufacturer Amgen Inc. is reporting that a new drug under testing has been shown to prevent bone loss in men with prostate cancer.

The drug, denosumab, was clinically tested on more than 1,400 men with non-metastatic prostate cancer undergoing androgen deprivation treatment. It showed that the drug helped reduce the risk the risk of osteoporosis and fracture in men receiving treatments for prostate cancer that can cause bone loss, the company said Monday